X
Pharma Advancement
  • Home
  • Articles
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    Avadel Pharmaceuticals Receives

    Avadel Pharmaceuticals Receives Orphan Drug Designation from FDA for LUMRYZ™ (sodium oxybate) for Extended-Release Oral Suspension for the Treatment of Idiopathic Hypersomnia

    Robots and AI in Drug

    Robots and AI in Drug Discovery Are Transforming Medicine

    Stringent Policy around COVID Vaccines Laid by FDA

    Stringent Policy around COVID Vaccines Laid by FDA

    Pharmaceutical-Chemicals Market Booms with Rising API Demand

    Pharmaceutical Chemicals Market Booms with Rising API Demand

    Next in Pharma 2025 Innovations

    Next in Pharma 2025: Innovations Shaping the Future

    Work Smart: Go for Hands-Free Lab Informatics at the Bench, Not Scribbled Notes and Delayed Documentation at Your Desk

    Clinical Development

    AI Revolutionizing Drug Discovery and Clinical Development

    Drug-Development

    China’s Super Me-Too Drug Development: A New Pharma Frontier

    Omics Based Clinical Trials

    Asia Pacific Omics-Based Clinical Trials Market Growth

  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us
No Result
View All Result
  • Home
  • Articles
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    Avadel Pharmaceuticals Receives

    Avadel Pharmaceuticals Receives Orphan Drug Designation from FDA for LUMRYZ™ (sodium oxybate) for Extended-Release Oral Suspension for the Treatment of Idiopathic Hypersomnia

    Robots and AI in Drug

    Robots and AI in Drug Discovery Are Transforming Medicine

    Stringent Policy around COVID Vaccines Laid by FDA

    Stringent Policy around COVID Vaccines Laid by FDA

    Pharmaceutical-Chemicals Market Booms with Rising API Demand

    Pharmaceutical Chemicals Market Booms with Rising API Demand

    Next in Pharma 2025 Innovations

    Next in Pharma 2025: Innovations Shaping the Future

    Work Smart: Go for Hands-Free Lab Informatics at the Bench, Not Scribbled Notes and Delayed Documentation at Your Desk

    Clinical Development

    AI Revolutionizing Drug Discovery and Clinical Development

    Drug-Development

    China’s Super Me-Too Drug Development: A New Pharma Frontier

    Omics Based Clinical Trials

    Asia Pacific Omics-Based Clinical Trials Market Growth

  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us
No Result
View All Result
Pharma Advancement
No Result
View All Result
Home Manufacturing

Alzheimers Disease Can Be Diagnosed By A Single Brain Scan

Content Team by Content Team
21st June 2022
in Manufacturing, Middle East and South Asia, News
Alzheimers Disease Can Be Diagnosed By A Single Brain Scan

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Doctors currently use a variety of tests to identify Alzheimer’s disease, including memory and cognitive tests that can take several weeks to set up and interpret. Only one of these is required in the new method, which is an MRI brain scan performed on typical 1.5 Tesla equipment present in most hospitals. The new method is based on an algorithm that was created for classifying cancer tumours. Researchers classified the brain into areas and assigned distinct attributes to each, teaching the algorithm to spot changes in these aspects that might effectively indicate the presence of Alzheimer’s disease.

Over 400 individuals with early and late-stage Alzheimer’s disease, healthy controls, and individuals with other neurological conditions had their brains scanned. They also used data from over 80 patients at Imperial College Healthcare NHS Trust who were having Alzheimer’s diagnostic tests.

The researchers discovered that an MRI-based machine learning system could effectively determine whether a patient had Alzheimer’s disease in 98% of the cases. In 79% of patients, it was also able to distinguish between early and late-stage Alzheimer’s disease with a high degree of accuracy.

Alzheimer’s disease is the most frequent cause of dementia in the United Kingdom, impacting over half a million people. Although the condition is most common in people over the age of 65, it can also affect people younger than that. Although there is no cure for Alzheimer’s disease, there are medications that can help ease the symptoms.

Patients will be able to seek advice and support, receive therapy to control their symptoms, and prepare for the future sooner thanks to the technique’s ability to analyse the disease in its earliest stages, when it can be difficult to diagnose. Currently, no other simple and generally available approaches can predict Alzheimer’s disease with this level of accuracy, said Professor Eric Aboagye of Imperial College London’s Department of Surgery and Cancer, who conducted the research.

Awaiting a diagnosis can be a nightmare for patients and their families. It would be really beneficial if one could reduce the amount of time patients have to wait, make diagnosis an easier procedure, and remove some of the ambiguity. This new method could also help doctors find early-stage patients in clinical trials of novel drugs or lifestyle changes, which is now difficult to do.

Previous Post

U.S. Officials Clear COVID-19 Jab For Infants, Preschoolers

Next Post

Third Rock Ventures $1 Billion Fund To Aid Biotech Startups

Related Posts

WuXi Biologics and Virogen Bio partner to advance VG712
News

WuXi Biologics and Virogen Bio partner to advance VG712

19th June 2025
Construction of WuXi Biologics Microbial Manufacturing Site
News

Construction of WuXi Biologics Microbial Manufacturing Site

19th June 2025
Beyfortus From Sanofi to Make Imprint in 2025 26 RSV Season
News

Beyfortus From Sanofi to Make Imprint in 2025-26 RSV Season

19th June 2025
Thermo-Fischer-Accelerator Drug Development an Ideal Choice
News

Thermo Fischer Accelerator Drug Development an Ideal Choice

19th June 2025
IQVIA Custom Built AI Agents for Life Sciences Healthcare
News

IQVIA Custom-Built AI Agents for Life Sciences, Healthcare

19th June 2025
SCHOTT Pharma Invests
News

SCHOTT Pharma Invests EUR 100 Million in RTU Cartridges

9th June 2025
Next Post
Third Rock Ventures $1 Billion Fund To Aid Biotech Startups

Third Rock Ventures $1 Billion Fund To Aid Biotech Startups

Qucik Links

  • Drug Development
  • Manufacturing
  • News
  • Events & Conferences
  • Newsletter Archive
Pharma Advancement

About Us

Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.

Subscribe Us

System

  • Search
  • Sitemap
  • RSS Feed

Resources

  • Advertise with us
  • Contact Us
  • Download Mediapack
  • Newsletters Archive

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

No Result
View All Result
  • Home
  • Articles
  • Drug Development
  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

Login to your account below

Forgotten Password?

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In